{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:30:19Z","timestamp":1777714219571,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000139","name":"U.S. Environmental Protection Agency","doi-asserted-by":"publisher","award":["STAR RD84045001"],"award-info":[{"award-number":["STAR RD84045001"]}],"id":[{"id":"10.13039\/100000139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES033243"],"award-info":[{"award-number":["R01 ES033243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES029911"],"award-info":[{"award-number":["R01 ES029911"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.taap.2025.117442","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T10:04:43Z","timestamp":1749981883000},"page":"117442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice"],"prefix":"10.1016","volume":"502","author":[{"given":"Volodymyr P.","family":"Tryndyak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose A.","family":"Willett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuolin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostiantyn","family":"Dreval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Hughes Hanks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick A.","family":"Beland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Rusyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor P.","family":"Pogribny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2025.117442_bb0005","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2025.117442_bb0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/CS20220572","article-title":"Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways","volume":"136","author":"Badmus","year":"2022","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.taap.2025.117442_bb0015","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/nu12061650","article-title":"Heightened plasma levels of transforming growth factor beta (TGF-\u03b2) and increased degree of systemic biochemical perturbation characterizes hepatic steatosis in overweight pediatric patients: a cross-sectional study","volume":"12","author":"Barretto","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.taap.2025.117442_bb0020","doi-asserted-by":"crossref","first-page":"17193","DOI":"10.1038\/s41598-017-17370-6","article-title":"The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease","volume":"7","author":"Cazanave","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117442_bb0025","doi-asserted-by":"crossref","first-page":"2479192","DOI":"10.1155\/2023\/2479192","article-title":"EMP1 as a potential biomarker in liver fibrosis: a bioinformatics analysis","volume":"2023","author":"Chen","year":"2023","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.taap.2025.117442_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155720","article-title":"The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPAR\u03b1","volume":"151","author":"Clavreul","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.taap.2025.117442_bb0035","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.3390\/ijms231911030","article-title":"S100 proteins in fatty liver disease and hepatocellular carcinoma","volume":"23","author":"Delangre","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2025.117442_bb0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/a-2186-3557","article-title":"Mechanisms of lipid droplet accumulation in steatotic liver diseases","volume":"43","author":"Dempsey","year":"2023","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.taap.2025.117442_bb0045","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3 - a biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.taap.2025.117442_bb0050","author":"FDA-CDER"},{"key":"10.1016\/j.taap.2025.117442_bb0055","doi-asserted-by":"crossref","first-page":"eaba4448","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.taap.2025.117442_bb0060","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","article-title":"Liver biopsy evaluation in MASH drug development: think thrice, act wise","volume":"81","author":"Harrison","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2025.117442_bb0065","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2025.117442_bb0070","first-page":"15","article-title":"Out-of-sample R2: estimation and inference","volume":"78","author":"Hawinkel","year":"2024","journal-title":"TAS"},{"key":"10.1016\/j.taap.2025.117442_bb0075","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.taap.2025.117442_bb0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.33549\/physiolres.935237","article-title":"Western diet-induced nonalcoholic fatty liver disease mice mimic the key transcriptomic signatures observed in humans","volume":"73","author":"Ishigure","year":"2024","journal-title":"Physiol. Res."},{"key":"10.1016\/j.taap.2025.117442_bb0085","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2025.117442_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217263","article-title":"Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis","volume":"14","author":"Kar","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2025.117442_bb0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2025.117442_bb0100","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41598-021-81959-1","article-title":"Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117442_bb0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.taap.2025.117442_bb0110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3350\/cmh.2020.0351","article-title":"Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome","volume":"27","author":"Lee","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.taap.2025.117442_bb0115","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.taap.2025.117442_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jgg.2021.09.009","article-title":"Tumor necrosis factor-\u03b1 signaling in nonalcoholic steatohepatitis and targeted therapies","volume":"49","author":"Lu","year":"2022","journal-title":"J. Genet. Genomics"},{"key":"10.1016\/j.taap.2025.117442_bb0125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Mari\u00f1o","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2025.117442_bb0130","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/jcm10061161","article-title":"Natural history of NAFLD","volume":"10","author":"Pais","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.taap.2025.117442_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101231","article-title":"Liver fibrosis in NAFLD\/NASH: from pathophysiology towards diagnostic and therapeutic strategies","volume":"95","author":"Parola","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.taap.2025.117442_bb0140","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.3390\/molecules26113316","article-title":"Collagen characterization in a model of nonalcoholic steatohepatitis with fibrosis; a call for development of targeted therapeutics","volume":"26","author":"Pellicano","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.taap.2025.117442_bb0145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.taap.2025.117442_bb0150","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/hep.31999","article-title":"Key characteristics of human hepatotoxicants as a basis for identification and characterization of the causes of liver toxicity","volume":"74","author":"Rusyn","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2025.117442_bb0155","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.1038\/s41598-017-10930-w","article-title":"Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis","volume":"7","author":"Ryaboshapkina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117442_bb0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3803\/EnM.2013.28.1.41","article-title":"Tumor necrosis factor-\u03b1 as a predictor for the development of nonalcoholic fatty liver disease: a 4-year follow-up study","volume":"28","author":"Seo","year":"2013","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.taap.2025.117442_bb0165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01889678","article-title":"Principal curves revisited","volume":"2","author":"Tibshirani","year":"1992","journal-title":"Stat. Comput."},{"key":"10.1016\/j.taap.2025.117442_bb0170","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/oby.2007.114","article-title":"ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats","volume":"16","author":"Toblli","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.taap.2025.117442_bb0175","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1096\/fj.12-209569","article-title":"Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism","volume":"26","author":"Tryndyak","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.taap.2025.117442_bb0180","doi-asserted-by":"crossref","first-page":"G232","DOI":"10.1152\/ajpgi.00225.2022","article-title":"Effect of an obesogenic high-fat and high-sucrose diet on hepatic gene expression signatures in male Collaborative Cross mice","volume":"324","author":"Tryndyak","year":"2023","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.taap.2025.117442_bb0185","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"10.1016\/j.taap.2025.117442_bb0190","article-title":"Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness","volume":"368","author":"Vollmer","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.taap.2025.117442_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-022-01764-1","article-title":"Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)","volume":"22","author":"Wagner","year":"2023","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.taap.2025.117442_bb0200","doi-asserted-by":"crossref","first-page":"eadi0759","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation \u2013 fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.taap.2025.117442_bb0205","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1038\/s41598-021-98806-y","article-title":"Single-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117442_bb0210","author":"Wickham"},{"key":"10.1016\/j.taap.2025.117442_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117046","article-title":"A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice","volume":"491","author":"Willett","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2025.117442_bb0220","doi-asserted-by":"crossref","first-page":"972320","DOI":"10.3389\/fphar.2022.972320","article-title":"The case for FAT10 as a novel target in fatty liver diseases","volume":"13","author":"Wimalarathne","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2025.117442_bb0225","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2025.117442_bb0230","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7150\/ijms.77367","article-title":"FAT10 silencing prevents liver fibrosis through regulating SIRT1 expression in hepatic stellate cells","volume":"20","author":"Zheng","year":"2023","journal-title":"Int. J. Med. Sci."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25002182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25002182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:10:26Z","timestamp":1777457426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X25002182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"alternative-id":["S0041008X25002182"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117442","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117442"}}